Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase

36Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Thrombin-activable fibrinolysis inhibitor (TAFI) is a carboxypeptidase found in human plasma, presumably as an inactive zymogen. The current dogma is that proteolytic activation by thrombin/thrombomodulin generates the active enzyme (TAFIa), which down-regulates fibrinolysis by removing C-terminal lysine residues from partially degraded fibrin. In this study, we have shown that the zymogen exhibits continuous and stable carboxypeptidase activity against large peptide substrates, and we suggest that the activity down-regulates fibrinolysis in vivo. © 2007 by The American Society for Biochemistry and Molecular Biology, Inc.

Cite

CITATION STYLE

APA

Valnickova, Z., Thøgersen, I. B., Potempa, J., & Enghild, J. J. (2007). Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase. Journal of Biological Chemistry, 282(5), 3066–3076. https://doi.org/10.1074/jbc.M606559200

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free